Dow Jones 10961.32 +162.09 8:27 am PDT, July 19, 2006 NASDAQ 2070.43 +27.21 For info, visit access.smallcapnetwork.com S & P 500 1255.27 +18.41 Change your subscription status here Russell 2000 697.51 +15.87 VOLUME 06: ISSUE 55 BioCurex is Creating A Buzz One of the great pleasures of working for the SmallCap Digest is the opportunity to see great corporate advancements unfold before our very eyes, as small companies start to get bigger for all the right reasons. Of all the leaps and bounds we see, none can be more satisfying -- on a professional as well as a personal level -- than a life-saving medical breakthrough. It sounds a little melodramatic (and maybe it is), but in the case of BioCurex (BOCX.PK), it's still very true. In the same sense, the longer we cover a company, the better we get to know it. Again, BioCurex is a good example. Our coverage of this company actually began in late 2003, yet, we're constantly finding new angles and factoids that make the company even more impressive. Plus, it doesn't hurt when the company also happens to be the sole developer of what is apparently the most effective prostate cancer detection test on the market. Although as investors we've trained ourselves to just skim headlines, you owe it to yourself to absorb all of this article. So, sit back, and get ready for a good read. For veteran SmallCap Digest readers, we'll get you up to speed on where the company is now. If you're new to SmallCap Digest, or new to BioCurex, prepare to be impressed.   Setting the Stage Today's edition is prompted by a press release from earlier this morning. As usual, a copy of the release appears below. Rather than rehash what you can read for yourself in the press release, we'll give you the basic scoop here. BioCurex is scheduled to present results from their RECAF? prostate cancer detection tests to the annual American Association for Clinical Chemistry (AACC) meeting next week. This is news-worthy for two reasons. First, RECAF ? works extremely well. Second, the meeting is the biggest of its kind in North America. So, it's a chance for BioCurex to turn a whole lot of the right heads (and we're sure they will). We think you'd be better served by some of the data we've gathered about RECAF ?, and prostate cancer testing in general. In some cases, the statistics are staggering. Did you know... Up to 30,000 men will die of prostate cancer this year About 200,000 men are diagnosed with prostate cancer every year Prostate cancer accounts for up to 30% of male cancer Prostate cancer is the ultimate cause in 11% of male mortality Incredible, isn't it? We're not trying to bring anybody down with the facts - we're just trying to set the stage for the good news. Just as incredible (in a good way) are the advancements being made in an effort to detect prostate cancer early and accurately. Treatment can be very effective against prostate cancer -- especially in the early stages. The only catch for cancer patients is this...they have to know about it. In that light, here are some equally shocking facts about the typical prostate cancer detection tests (PSA).   "The Test" Did you know... Only about 1/3 of 'positive' PSA test results actually indicate cancer (the other 2/3 of the 'positives' are false positives) Up to half of 'negative' PSA test results actually should be positives (as the patient really does have cancer, despite the test saying they don't) You don't have to be a doctor to know those kinds of results really aren't very helpful. In determining whether or not a male had prostate cancer, you would have been just as successful by tossing a coin. In fact, if anything, the errant results are actually dangerous. Thousands of men may actually have prostate cancer, and not know it, and therefore not treat it. Simultaneously, thousands of men may undergo a biopsy surgery and not really need it. Even though it's a fairly routine procedure now, there's never good reason to go under the knife if you don't have to. If you're like us, you might think the stats are downright bizarre. Why would the medical community employ a test like this, knowing the results are very likely to be wrong? In simplest terms, there's not much choice...at least not that most people are aware of. The problem has been solved though, by our friends at BioCurex. What would you say if the average success rate of the PSA test went from 40% (a rough estimate of how often one gets a false positive or false negative) to 90%? A big deal? You bet it is. Well, that's precisely what happened. Enter RECAF?. Although RECAF? has a role in detection of many types of cancer, today's press release specifically focuses on the improvement in prostate cancer detection. For lack of a better way of saying it, more than doubling the success rate of the PSA test is just plain huge.   The Opportunity What's even more amazing than the incredible RECAF? test results is the general lack of knowledge about the test and the company behind it. That's why the company is going to the AACC conference -- to get the word out. Enter us -- the SmallCap Digest. We're also all about telling the great stories of up-and-coming companies, while simultaneously helping our readers make some money. So, needless to say, we're still bullish on BioCurex; we just have to believe once the medical world opens their eyes and ears to this epic improvement over the PSA test, its utilization will go through the roof. With that in mind, here's the last set of stats... The average prostate cancer test kit costs between $10 and $20 to manufacture The PSA-test market is a half-billion dollar market (yes, with a 'b') Abbott Laboratories (NYSE: ABT) is currently the sole marketer/distributor for the BioCurex RECAF? test Abbott Laboratories controls about 1/3 of the medical diagnostic equipment market You can slice the data up a lot of different ways, but there's only one way we're really interested in -- the bottom line. Assuming Abbott maintains its relative market share in just the PSA testing market, that's still more than a hundred million dollars that could potentially get directed toward the Abbott/BioCurex partnership. Those proportions aren't the way things are right now, but it's definitely within the realm of possibility in the future. As for the stock, the market's overall weakness over the last few weeks has infected BioCurex shares as well. But, we've seen a couple of deep intra-day lows in the last three days that could signal shares are at a bottom. And quite frankly, the dip all the way back to the current price of 58 cents is actually a blessing. Anybody who missed an entry opportunity before now has a chance to get in at a relatively low point. Just for some perspective on how big the opportunity is, we first recommended BOCX on October 23rd of 2003, when shares were trading at 17 cents. Between here and there, that's a 241% gain (and it had been much higher than that). Best of all, the reason this stock is worth buying is rooted in what the company is actually doing. RECAF? really is a medical breakthrough, and a giant opportunity for BioCurex. Here's the release.   BioCurex Presents Results At The Largest Clinical Lab Meeting In North America. RICHMOND, British Columbia, July 18, 2006. -- BioCurex Inc. (BOCX.PK) announced today that it will be presenting results obtained with its RECAFTM blood test at the American Association for Clinical Chemistry (AACC) Annual Meeting being held in Chicago on July 23-27, 2006. The presentation will focus on results obtained with the Company's RECAF test of serum samples from normal individuals, prostate cancer patients and patients with benign prostate lesions. The main problem in prostate cancer diagnosis is not to discriminate patients with cancer from normal individuals, but rather to discriminate between prostate cancer and benign prostate conditions. In this set of samples, which comprised sera from 100 known cancer patients and 30 patients with benign lesions, the standard PSA test showed a sensitivity of 48% with 60% specificity. This means that the test missed over half the cancers (100-48=52) and that 40% (100-60) of the patients were subjected to an unnecessary biopsy of their prostate. Adding a second variant of the test called "free PSA", the specificity was increased to 70% at the expense of doubling the cost. This also meant that 30% of patients with benign lesions would still be unnecessarily subjected to a biopsy. Using the company's RECAF test on the same cancer and benign samples, the sensitivity was 90% with a specificity of 84%. When the cancer samples were compared with samples from normal individuals, both the sensitivity and the specificity of the RECAF test approached 100%. About the AACC: The AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and clinical laboratory science disciplines. Founded in 1948, the society has 9,500 members and is headquartered in Washington, DC. The AACC's annual scientific meeting and technology exposition is the leading event in the clinical laboratory profession, attracting 17,000 participants from 110 countries in 2005. The Clinical Laboratory Exposition is the largest exposition in the world, dedicated exclusively to clinical laboratory science, with over 1,600 booths and more than 600 participating organizations attending last year. For further information about on the AACC visit: www.aacc.org About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAFTM Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. To read more about the Company, please visit the News section in our web site (www.biocurex.com). Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. Contact: Ricardo Moro BioCurex, Inc. Tel: (604) 207-9150   We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 On The Go Ships Out Massive Order Cha-Ching! On The Go Technologies (OTCBB: OGHC) just shipped $313,400 worth of goods to an internet television distribution company with an international footprint. Is that a big deal? Definitely! Just for perspective, don't forget On The Go's biggest sale ever was the $827,000 order placed about a month ago. The dollar amount here isn't quite as high, but on a relative basis, it's still a nice little padding for the top (and bottom) line. And for those who are still trying to figure out what 'internet television distribution' is, that's just the fancy way of saying 'we can show you cable TV on your computer just using an internet connection'. The benefit to the user is obviously mobility. Hence the name 'On The Go Technologies'. .   Cel-Sci Files Quarterly SEC Report Cel-Sci Corporation (AMEX: CVM) has just submitted results for the first half of their fiscal 2006. There were some noteworthy changes we saw on a quarterly and six-month (year-over-year) basis, but overall, nothing was a show-stopper. One of the biggest changes between last quarter (ending March 31st) and the end of last fiscal year was the cancellation of over $800,000 in derivative liabilities. Total liabilities now are less than 1/3 of what they were just six months ago. Revenue was down, as some of the company's funding grants expired in the last few months. Cel-Sci is pro-actively seeking other grant funding. And, administrative expenses were up, mostly as a result of employee stock option expenses. That's the flipside of the major reduction in the derivative liabilities total. For the complete 10Q report, click here. Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Digest, the Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCD") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCD is owned and operated by TGR Group, LLC ("TGR"). TGR is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCD. To the degrees enumerated herein, SCD should not be regarded as an independent publication. Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://www.smallnetwork.net/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Under SEC Rule 144, all one million issued restricted shares are now eligible for sale into the public market. TGR Group has submitted the appropriate filings to sell the shares. In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares. TGR Group LLC has been paid a fee of $30,000 cash and 1,000,000 shares of newly issued, restricted stock by On the Go Technologies Group for coverage of the Company. TGR Group LLC has been paid a fee of $25,000 and 150,000 shares of newly issued restricted stock by Cel-Sci for coverage of the Company. Additionally, back in November of 2002, TGR Group LLC was paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company until November of 2003. The aforementioned 250,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in February of 2006. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed. All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCD is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.